It was a low-key week for the biotech sector. While Amgen AMGN offered to buy a drug discovery platform biotech company, the FDA approved the label expansion of lead drugs of Celgene CELG and Incyte INCY.
Recap of the Week’s Top Stories:
Amgen to Acquire Drug Discovery Platform: Amgen announced that it has offered to acquire Denmark-based drug discovery platform biotech company, Nuevolution, for $3.36 per share (32.5 Swedisk Krona) in cash. Amgen’s offer represents a premium of 169% over the closing price of Nuevolution shares on May 21, valuing it at approximately $167 million (1610 Swedisk Krona). The board of Nuevolution unanimously recommended an acceptance of the offer and three top shareholders, representing 59% shareholdings, have also undertaken to accept the offer. Per the press release, Amgen will provide the offer document on Jun 12. The acceptance period for the offer will commence from Jun 13 and is expected to end on Jul 4. Amgen expects to settle the offer by Jul 15.
Amgen will offer cash and restricted stock compensation arrangements to retain the full-time employees of Nuevolution. Amgen has collaborated with Nuevolution since October 2016 for discovering drugs targeting multiple indications including two cancer programs. The acquisition will bring the Nuevolution’s drug-discovery platform in-house, which may boost Amgen's ability to discover novel small molecules against difficult-to-drug targets and make the process faster and more efficient.
FDA Nod for Label Expansion of Incyte’s Jakafi: Incyte announced that the FDA has approved a label expansion of its lead drug, Jakafi (ruxolitinib). Jakafi is now approved for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older. The approval was based on encouraging data from REACH1, an open-label, single-arm, multicenter study of Jakafi in combination with corticosteroids in patients with steroid-refractory grade II-IV acute GVHD.
The FDA had earlier granted Breakthrough Therapy designation and Orphan Drug status to Jakafi for the treatment of patients with steroid-refractory acute GVHD. The supplemental New Drug Application (sNDA) was reviewed under the FDA’s Priority Review program. Per Incyte, this is the first and only FDA-approved treatment for the aforementioned indication. The approval comes as a sign of relief for investors as the FDA had earlier extended the review period of the sNDA. Jakafi is approved in the United States for the treatment of patients with polycythemia vera (“PV”), who have had an inadequate response to or are intolerant to hydroxyurea. The drug is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF and post-essential thrombocythemia MF.
FDA Nod for Label Expansion of Celgene’s Revlimid: Celgene announced that the FDA has approved a label expansion of lead drug, Revlimid. The drug has been approved in combination with a Rituxan product (R²) for the treatment of adult patients with previously treated follicular lymphoma (FL) or marginal zone lymphoma (MZL). The approval was primarily based on results from the randomized, double-blind, phase III AUGMENT study, which evaluated the efficacy and safety of the R² combination versus rituximab plus placebo in patients with previously treated FL. The label expansion of the drug will further boost sales of the drug. A marketing authorization application for R2 is currently under review by the European Medicines Agency for the treatment of relapsed/refractory FL and MZL.
Celgene currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
BioMarin’s Gene Therapy Meets Criteria in Phase III: BioMarin Pharmaceutical Inc. BMRN announced positive results from a late-stage study on investigational gene therapy, valoctocogene roxaparvovec. The candidate achieved pre-specified clinical criteria for regulatory review in the United States and Europe in adults suffering from severe hemophilia A. As of May 28, eight patients in the 20-patient cohort of the phase III GENEr8-1 study achieved Factor VIII levels of 40 international units per deciliter (IU/dL) or more at 23 to 26 weeks. Consequently, the pre-specified criterion for Factor VIII activity levels was met.
Medical - Biomedical and Genetics Industry 5YR % Return
Medical - Biomedical and Genetics Industry 5YR % Return
The NASDAQ Biotechnology index has lost 1.5% in the past four trading sessions. Among the major biotech giants, Gilead lost 3.8% in the period. Over the past six months, shares of Celgene have surged 32.9% whereas Biogen stock has lost 32.1%. (See the last biotech stock roundup here: Biotech Stock Roundup: Label Expansion for CELG’s Drugs, Setback for IMGN)
What's Next in Biotech?
Stay tuned for updates from the ASCO meet scheduled next week.
Will you retire a millionaire?
One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”
Click to get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Celgene Corporation (CELG) : Free Stock Analysis Report
Amgen Inc. (AMGN) : Free Stock Analysis Report
Incyte Corporation (INCY) : Free Stock Analysis Report
BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research